Formerly in the fold of Nestlé, Galderma now stands on its own two feet. Its sales increased by 8.5% last year, and exceeded $4 billion for the first time.
It offers injectable products and drugs intended to treat skin diseases, such as acne (Differin) or rosacea (Soolantra). However, the boom in water-free cosmetics is solid, but the returns aren't as good as they used to be. This article is reserved for subscribers. You have 80% left to discover.